Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.67 |
| ▸ | MELK | Q14680 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031181 | 0.87 | THRB (0.71) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL24004598 | 0.84 | TSHR (0.67) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL13528242 | 0.83 | MAPT (0.78) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL30317732 | 0.83 | HDAC6 (0.76) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL24030718 | 0.81 | HDAC6 (0.76) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL24031144 | 0.81 | HDAC6 (1.00) | HDAC6HDAC8HDAC1HDAC11MELK | |
| SCHEMBL28354153 | 0.80 | HDAC6 (0.68) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL24247586 | 0.79 | HDAC1 (0.69) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL16674525 | 0.78 | TSHR (0.73) | MAPTHDAC6HDAC8HDAC1HDAC11 | |
| SCHEMBL24030751 | 0.77 | HDAC6 (0.70) | MAPTHDAC6HDAC8HDAC1HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621317-B | Inhibitors of Histone Deacetylase (HDACS) | 安基生技新药股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2022-12-27 | — | — | US | disclosed |
| EP-3624804-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2022-02-16 | — | — | EP | disclosed |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | HDAC1, HDAC3, HDAC2 | MAPT 4540/4885HDAC6 11/4885HDAC8 6/4885 |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | HDAC1, HDAC3, HDAC2 | MAPT 4410/4885HDAC6 8/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.